SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
A case of a carcinoma of the urachus is described with particular reference to special pathological anatomy and clinical treatment. Due to the rareness of this kind of tumour and its unspecific symptoms its diagnosis is difficult. The therapy corresponds to the general rules of carcinoma surgery.
A gastroduodenal combination preparation was introduced at a deliberately high dosage into a clinical treatment schema. A marked improvement of the subjective symptoms already appeared after a short treatment in hospital, pain in particular being rapidly affected. Younger patients tolerated the preparation excellently, older ones had a marked sedation. Because of the danger of concealment, stenoses in the region of the gastrointestinal tract, ileus and preileus are particular contraindications. The dosage of 3 X 3 to 3 X 4 dragees should be reserved for hospital treatment. The dosage of 3 X 1 dragee for ambulant practice and also for prolonged therapy (ca. 6-8 weeks) is unobjectionable, reference being made to possible initial tiredness and disturbances of accomodation.
Reference is made to the level of development of psychiatry in the USSR and the general principles of psychiatric care accepted in the country. Part of the development in the GDR is then described, followed by an argument in favour of day and night care for patients. This is an area where much remains to be done. This partial clinical treatment is to fill the gap between inpatient and outpatient facilities and should be available in the residential area of the patient.
Narcotic antagonist (naltrexone) treatment experience with 22 opioid addicts over a 29-month period shows that the mean duration of receipt of naltrexone was 6.2 weeks, and 12 subjects (55%) continued in treatment after cessation of naltrexone for an average of 5.6 weeks. Analysis of physical and behavioral measured revealed no toxicity, indicating that naltrexone appears to be a safe drug. Clinical evaluation of the patients receiving naltrexone suggests that ingestion of naltrexone provides a degree of external control, reducing the preoccupation with heroin and releasing energy for the pursuit of other goals. Subject follow-up at an average of 45.3 weeks after cessation of naltrexone indicated that 11 (58%) were known to be abstinent, and 9 (47%) subjects were employed compared with 3 (16%) employed at the onset of treatment.
Eighteen patients with polymyalgia rheumatica had corticosteroid treatment withdrawn abruptly under close observation. In each case polymyalgic symptoms reappeared but were controlled rapidly when prednisolone was reintroduced. Prednisolone withdrawal was then started by slow decrements of dose. In no patient was it possible to withdraw prednisolone treatment, after using either method, during the period of observation.
INTRODUCTION: Osteosarcoma (OS) is a common bone malignancy in adolescents and older adults and typically develops in the long bones. Outcomes in advanced cases remain poor despite the use of chemotherapeutic drugs like doxorubicin, methotrexate, and cisplatin, underscoring the urgent need for safer, more focused treatments. METHODS: A comprehensive review of clinical trials and literature identified emerging OS therapies targeting DNA repair, immune pathways, and tumor-specific markers. The EMA's approval of Mepact for nonmetastatic OS underscores the shift toward precision treatments and the evolving landscape of OS management. Patent protection can influence the pricing and accessibility of innovative medicines for OS by affecting market exclusivity and competition. RESULTS: According to recent research, bone morphogenetic protein (BMP), RB, and TP53 gene alterations both contribute to the development of OS. These results highlight the importance of conducting further proteomic and genomic research in order to develop focused and efficient treatment plans. Furthermore, patent protection stimulates innovative drug development by encouraging research investment and faster launches, but restricts affordability due to exclusivity, posing a policy dilemma. DISCUSSION: Treatment for OS is still challenging, particularly in high-grade and metastatic cases when conventional chemotherapy is frequently harmful and unsuccessful. While new targeted medicines and advances in understanding bone cell dynamics and genetic abnormalities such as TP53, RB, and BMPs offer hope for more accurate, less invasive treatments, the approval of Mapact represents progress. CONCLUSION: The necessity for integrated therapies combining immunotherapy, targeted delivery, and molecular insights to enhance OS treatment results is highlighted by developments in genomics and bone remodeling.
Starting from the U-test (see Buck 1975), for 2 independent samples of differences (e.g. pre-post differences), a corresponding test for 2 dependent samples of differences of pre- and post-measurements of 2 treatments (e.g. verum vs. placebo) is described (matched-pairs differences-W-test). Clinically relevant applications (verum vs. placebo) of the matched-pairs differences-W-test are mentioned and discussed as to their restrictions.
Explore the source record for details and available documents.
The relationship between periodontal disease and dysfunction of the stomatognathic system was examined with the usual analysis of function in the context of a clinical study. In addition to neuromuscular incoordination, premature centric contacts deflect the mandible from a muscularly stable contact position and traumatize the periodontium mechanically. After suitable treatment, the causes of functional damage to the tooth attachment apparatus may be demonstrated in connection with an exact clinical registration of the findings by a simple instrumental analysis of function. This analysis may be adequately carried out with a semiadjustable articulator together with a rapidly transmitted curve.
INTRODUCTION: Sutimlimab, a classical complement pathway (CP) inhibitor, was approved in 2022 in the US, EU, and Japan for the treatment of cold agglutinin disease (CAD), a rare form of autoimmune hemolytic anemia (AIHA) characterized by CP‑mediated extravascular hemolysis and circulatory symptoms related to IgM‑mediated red blood cell (RBC) agglutination. This review reexamines the clinical trial data and compares those findings with published real‑world experience (RWE), providing clinicians with efficacy and safety data that extend beyond the clinical trial experience in this rare AIHA. AREAS COVERED: The first-in-human trials, the two seminal clinical trials (CARDINAL and CADENZA), and the published post‑marketing RWE are presented. Literature searches for CAD and sutimlimab were conducted in PubMed and in abstracts from ASH and EHA from 2016 to present. All articles and abstracts regarding sutimlimab and CAD were included. EXPERT OPINION: Long-term data from clinical trials and published RWE support the safety and efficacy of sutimlimab. Targeting the CP as primary therapy for CAD offers a unique, targeted management strategy that minimizes exposure to immunosuppressive regimens. The rapid onset of sutimlimab's activity provides a potentially lifesaving treatment option in situations where immediate control of hemolysis is critical. Opportunities remain to increase our understanding of the role of complement inhibition combined with immunosuppressive therapy in CAD. The impact of complement inhibition on morbidity and mortality in CAD remains to be determined.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A review of all morphine classical conditioning studies performed since Pavlov reveals significant shifts in methodological and conceptual thinking during the past 7 decades. These shifts have tended to obscure the fact that a great deal of basic data are still needed before morphine classical conditioning can be understood. These data are needed to help clarify the relationship between drug conditioning and drug addiction. Recent evidence, for example, suggests that once morphine autonomic conditional reactions are established, they are highly resistant to extinction. The inclusion of these types of data in any conceptualization of drug dependency would appear to be of help in the formulation of new clinical approaches to this problem.
The rate of utero-placental blood flow depends on functional components (perfusion pressure and flow resistance within the area of the vascular bed of the placenta), as well as on morphological factors (regressive changes in the placenta). Different primary maternal conditions and diseases may lower the rate of placental flow, leading to placental insufficiency; the highest percentage, by far, of placental dysfunction is found in patients suffering from gestosis. Hypocirculation initially present in cases of EPH gestosis and caused by arteriolar spasms triggers off a vicious circle involving placental infarction and severe reduction in the utero-placental perfusion rate. This in turn leads to fetal hypotrophy, a high rate of premature births and perinatal mortality. Verification of HPL, HCG, alpha-Fetoprotein or E3 in maternal serum and amniotic fluid or urine greatly improved the recording of partial placental functions. Along with ultrasonic biometry, cardiotocography and amnioscopy, these hormonal parameters allow only indirect assessment of the placental function. On the other hand, measurements of the utero-placental flow offers a direct approach. In order to evaluate the placental flow measurements it is imperative to obtain a curve indicating the course over the last third of the pregnancy-in addition to establishing a general normal range. In case of placental insufficiency, it is necessary to determine whether this is due to functional disorders alone, or to more extenisve morphological changes. A placental perfusion test (PPT) was developed in order to make this distinction. Beta2-mimetic treatment is indicated if functional factors predominate, whereby it appears essential to obtain the requisite experimental data for precise quantification of beta-mimetic action.
Effectiveness and tolerance of Defluina was studied in a selective open trial including 30 patients (17 males, 13 females, mean age 70 years) suffering from peripheral arterial occlusive diseases of different stages. All patients were treated with Defluina, 20 drops thrice a day during a mean period of 30 days. Simultaneous application of further peripheral vasodilators was excluded. Subjective and objective parameters (pulse, Ratschow's test, walking distance) of 27 patients (15 males, 12 females) were evaluated. After 4 weeks of therapy an improvement of all parameters especially of the walking distance was observed. Within 4 weeks 3 of 5 ulcera cruris as well as an initially existing gangrene were closed. Deflunia was well tolerated by 25 patients, very well tolerated by 2. The therapy was discontinued in 3 patients: 2 because of unchanged complaints after 13 and 20 days of therapy, 1 after 17 days due to dull gastric pain following intake of the drug. Cardiac side-effects or steal phenomena were not observed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.